In short
This article summarizes several clinical trials investigating the use of MPS-112, also known as TEDOPI, for treating various types of cancer. TEDOPI is a cancer vaccine being studied as a potential new immunotherapy option for patients with advanced cancers like non-small cell lung cancer, ovarian cancer, and pancreatic cancer.
What is MPS-112?
MPS-112 is one of the active ingredients in an experimental cancer vaccine called OSE2101 (also known as Tedopi). This vaccine is being developed as a potential new treatment for several types of cancer. It is considered a therapeutic cancer vaccine, which means it is designed to treat existing cancers rather than prevent them.
How Does MPS-112 Work?
OSE2101, which contains MPS-112, works by stimulating the body's immune system to fight cancer cells. It is made up of 10 synthetically manufactured peptides (small protein fragments) that are designed to activate T cells, a type of immune cell that can recognize and attack cancer cells. The vaccine is specifically designed for patients who have a certain protein on their cells called HLA-A2, which is present in about 45% of the population.
What Types of Cancer is MPS-112 Being Studied For?
MPS-112, as part of the OSE2101 vaccine, is currently being studied in clinical trials for several types of cancer:
- Non-Small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer.
- Ovarian Cancer: Specifically for patients with platinum-sensitive recurrent ovarian cancer.
- Pancreatic Cancer: For patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Current Clinical Trials
Several clinical trials are currently underway to test the effectiveness and safety of OSE2101 (containing MPS-112) for different types of cancer:
- ARTEMIA Study: This is a phase 3 trial comparing OSE2101 to chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer who have previously received immunotherapy.
- TEDOVA Study: This is a phase 2 trial testing OSE2101 alone or in combination with another immunotherapy drug (pembrolizumab) for patients with recurrent ovarian cancer.
- TEDOPAM Study: This is a phase 2 trial evaluating OSE2101 in combination with chemotherapy for patients with advanced pancreatic cancer.
Potential Benefits
The potential benefits of MPS-112 (as part of OSE2101) that researchers are investigating include:
- Improved overall survival for cancer patients
- Better quality of life compared to standard chemotherapy
- Potential for longer-lasting responses to treatment
- Possibility of combining with other cancer treatments for enhanced effects
Side Effects and Safety
As with any medical treatment, OSE2101 may cause side effects. The full range of potential side effects is still being studied in clinical trials. Some possible side effects may include:
- Injection site reactions
- Fatigue
- Immune-related side effects
It's important to note that the safety profile is still being evaluated in ongoing clinical trials.
Who May Be Eligible?
Eligibility for treatment with OSE2101 (containing MPS-112) varies depending on the specific clinical trial and type of cancer. However, some general criteria include:
- Having HLA-A2 positive cancer cells (determined by a blood test)
- Having advanced or metastatic cancer that has not responded to or has progressed after standard treatments
- Being 18 years or older
- Having adequate organ function and overall health status
Conclusion
MPS-112, as a component of the OSE2101 cancer vaccine, represents a promising new approach in cancer treatment. By harnessing the power of the immune system, it offers hope for patients with various types of advanced cancers. While the results of ongoing clinical trials are eagerly awaited, it's important to remember that this treatment is still experimental. Patients interested in this treatment should discuss with their healthcare providers whether participating in a clinical trial might be appropriate for their individual situation.